$RXST
RxSight, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024022073 Filed on February 28, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $29.51M $28.58M $89.08M
YoY Change 68.75% 77.65% 81.77%
Cost Of Revenue $8.827M $10.93M $35.31M
YoY Change 23.92% 26.08% 27.59%
Gross Profit $20.69M $17.65M $53.77M
YoY Change 99.55% 137.86% 152.09%
Gross Profit Margin 70.09% 61.77% 60.36%
Selling, General & Admin $23.32M $21.18M $74.80M
YoY Change 43.49% 34.03% 27.5%
% of Gross Profit 112.76% 119.98% 139.12%
Research & Development $8.031M $7.292M $29.05M
YoY Change 11.42% 10.5% 11.82%
% of Gross Profit 38.83% 41.31% 54.03%
Depreciation & Amortization $1.115M $1.084M $4.078M
YoY Change 16.75% 12.8% 4.99%
% of Gross Profit 5.39% 6.14% 7.58%
Operating Expenses $31.36M $28.51M $103.9M
YoY Change 33.64% 27.19% 22.69%
Operating Profit -$10.67M -$10.85M -$50.09M
YoY Change -18.53% -27.61% -20.9%
Interest Expense $6.000K $1.657M $3.308M
YoY Change -99.6% -369.43% -33.12%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$9.091M -$9.195M -$48.59M
YoY Change -31.19% -41.08% -27.21%
Income Tax $9.000K -$18.00K $20.00K
% Of Pretax Income
Net Earnings -$9.100M -$9.177M -$48.61M
YoY Change -31.12% -41.21% -27.19%
Net Earnings / Revenue -30.83% -32.11% -54.57%
Basic Earnings Per Share -$0.25 -$1.41
Diluted Earnings Per Share -$0.25 -$0.26 -$1.41
COMMON SHARES
Basic Shares Outstanding 36.99M 35.86M 34.46M
Diluted Shares Outstanding 36.84M 34.46M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $125.4M $127.2M $127.2M
YoY Change -18.57% 20.21% 20.21%
Cash & Equivalents $32.65M $9.692M $9.692M
Short-Term Investments $92.71M $117.5M $117.5M
Other Short-Term Assets $2.955M $3.523M $3.523M
YoY Change -1.24% 18.94% 18.94%
Inventory $18.70M $17.42M $17.42M
Prepaid Expenses
Receivables $21.55M $20.28M $20.28M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $168.6M $168.4M $168.4M
YoY Change -10.18% 25.16% 25.16%
LONG-TERM ASSETS
Property, Plant & Equipment $11.62M $10.84M $13.29M
YoY Change 18.49% 6.93% -5.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $226.0K $147.0K $858.0K
YoY Change -69.71% -80.83% -43.85%
Total Long-Term Assets $14.61M $14.14M $14.14M
YoY Change -1.75% -9.39% -9.39%
TOTAL ASSETS
Total Short-Term Assets $168.6M $168.4M $168.4M
Total Long-Term Assets $14.61M $14.14M $14.14M
Total Assets $183.2M $182.6M $182.6M
YoY Change -9.56% 21.57% 21.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.057M $3.863M $3.863M
YoY Change 36.05% 48.86% 48.86%
Accrued Expenses $13.25M $15.24M $12.40M
YoY Change 19.94% 20.26% 14.72%
Deferred Revenue $2.045M
YoY Change 51.71%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $24.00K $37.00K $37.00K
YoY Change -78.95% -75.66% -75.66%
Total Short-Term Liabilities $18.33M $20.90M $20.90M
YoY Change 23.21% 21.27% 21.27%
LONG-TERM LIABILITIES
Long-Term Debt $120.0K $118.0K $118.0K
YoY Change -99.7% -99.71% -99.71%
Other Long-Term Liabilities $788.0K $1.167M $1.167M
YoY Change -66.3% -58.51% -58.51%
Total Long-Term Liabilities $908.0K $1.285M $1.285M
YoY Change -97.87% -97.01% -97.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.33M $20.90M $20.90M
Total Long-Term Liabilities $908.0K $1.285M $1.285M
Total Liabilities $19.24M $22.19M $22.19M
YoY Change -66.56% -63.18% -63.18%
SHAREHOLDERS EQUITY
Retained Earnings -$603.7M -$594.6M
YoY Change 7.96% 8.9%
Common Stock $37.00K $36.00K
YoY Change 8.82% 28.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $163.9M $160.4M $160.4M
YoY Change
Total Liabilities & Shareholders Equity $183.2M $182.6M $182.6M
YoY Change -9.56% 21.57% 21.57%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$9.100M -$9.177M -$48.61M
YoY Change -31.12% -41.21% -27.19%
Depreciation, Depletion And Amortization $1.115M $1.084M $4.078M
YoY Change 16.75% 12.8% 4.99%
Cash From Operating Activities -$9.309M -$8.301M -$41.59M
YoY Change -47.6% -40.08% -29.32%
INVESTING ACTIVITIES
Capital Expenditures $1.967M $1.591M $4.814M
YoY Change 163.32% 339.5% 101.17%
Acquisitions
YoY Change
Other Investing Activities $26.24M $6.157M -$17.32M
YoY Change -155.11% -42.82% -140.89%
Cash From Investing Activities $24.27M $4.566M -$22.13M
YoY Change -150.19% -56.12% -155.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.473M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.992M 3.562M 61.52M
YoY Change -87.76% -43.52% 871.64%
NET CHANGE
Cash From Operating Activities -9.309M -8.301M -41.59M
Cash From Investing Activities 24.27M 4.566M -22.13M
Cash From Financing Activities 7.992M 3.562M 61.52M
Net Change In Cash 22.95M -173.0K -2.192M
YoY Change -2892.46% -106.05% -82.57%
FREE CASH FLOW
Cash From Operating Activities -$9.309M -$8.301M -$41.59M
Capital Expenditures $1.967M $1.591M $4.814M
Free Cash Flow -$11.28M -$9.892M -$46.41M
YoY Change -39.08% -30.42% -24.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001111485
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNet
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20231231#LeaseLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20231231#LeaseLiabilitiesCurrent
CY2023Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20231231#LeaseLiabilitiesCurrent
CY2022Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20231231#LeaseLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20231231#LeaseLiabilitiesNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20231231#LeaseLiabilitiesNoncurrent
CY2023Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20231231#LeaseLiabilitiesNoncurrent
CY2022Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://rxsight.com/20231231#LeaseLiabilitiesNoncurrent
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-40690
CY2023 dei Entity Registrant Name
EntityRegistrantName
RxSight, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3268801
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Columbia
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Aliso Viejo
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92656
CY2023 dei City Area Code
CityAreaCode
(949)
CY2023 dei Local Phone Number
LocalPhoneNumber
521-7830
CY2023 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
CY2023 dei Trading Symbol
TradingSymbol
RXST
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
869000000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36987556
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
Irvine, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9692000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11834000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
117490000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
93968000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20281000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10956000
CY2023Q4 us-gaap Inventory Net
InventoryNet
17421000
CY2022Q4 us-gaap Inventory Net
InventoryNet
14835000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3523000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2962000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
168407000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
134555000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10841000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10138000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2444000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3943000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
711000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
761000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
147000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
767000
CY2023Q4 us-gaap Assets
Assets
182550000
CY2022Q4 us-gaap Assets
Assets
150164000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3863000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2595000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15239000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12672000
CY2023Q4 rxst Lease Liabilities Current
LeaseLiabilitiesCurrent
1801000
CY2022Q4 rxst Lease Liabilities Current
LeaseLiabilitiesCurrent
1970000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20903000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17237000
CY2023Q4 rxst Lease Liabilities Noncurrent
LeaseLiabilitiesNoncurrent
1211000
CY2022Q4 rxst Lease Liabilities Noncurrent
LeaseLiabilitiesNoncurrent
2856000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
0
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
40169000
CY2023Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
74000
CY2022Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
0
CY2023Q4 us-gaap Liabilities
Liabilities
22188000
CY2022Q4 us-gaap Liabilities
Liabilities
60262000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36139513
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36139513
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28268389
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28268389
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
36000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.41
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.41
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.41
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34455111
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
754971000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
636001000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-95000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-594640000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-546032000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
160362000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
89902000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
182550000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
150164000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
89077000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49005000
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
35312000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
27677000
CY2023 us-gaap Gross Profit
GrossProfit
53765000
CY2022 us-gaap Gross Profit
GrossProfit
21328000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
74799000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
58665000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29051000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25981000
CY2023 us-gaap Operating Expenses
OperatingExpenses
103850000
CY2022 us-gaap Operating Expenses
OperatingExpenses
84646000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-50085000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-63318000
CY2023 us-gaap Interest Expense
InterestExpense
3308000
CY2022 us-gaap Interest Expense
InterestExpense
4946000
CY2023 us-gaap Interest And Other Income
InterestAndOtherIncome
6574000
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
1517000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1769000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48588000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66747000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-48608000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-66756000
CY2023 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
83000
CY2022 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-66000
CY2023 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
7000
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-9000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
90000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
75000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48518000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66831000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.41
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34455111
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27661982
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27661982
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
138242000
CY2022 rxst Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount
SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
841000
CY2022 rxst Shares Redeemed For Employee Tax With Holdings Amount
SharesRedeemedForEmployeeTaxWithHoldingsAmount
-643000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11397000
CY2022 rxst Shares Issued For The Employee Stock Purchase Plan Amount
SharesIssuedForTheEmployeeStockPurchasePlanAmount
937000
CY2022 rxst Issuance Of Common Stock In At The Market Offerings Net Of Issuance Costs Amount
IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount
5959000
CY2022Q4 rxst Other Comprehensive Loss
OtherComprehensiveLoss
-75000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-66756000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
89902000
CY2023 rxst Shares Issued For The Exercise Of Stock Options And Vesting Of Restricted Stock Units Amount
SharesIssuedForTheExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsAmount
8352000
CY2023 rxst Shares Redeemed For Employee Tax With Holdings Amount
SharesRedeemedForEmployeeTaxWithHoldingsAmount
-1423000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15746000
CY2023 rxst Shares Issued For The Employee Stock Purchase Plan Amount
SharesIssuedForTheEmployeeStockPurchasePlanAmount
1121000
CY2023 rxst Issuance Of Common Stock In At The Market Offerings Net Of Issuance Costs Amount
IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCostsAmount
53600000
CY2023 rxst Issuance Of Common Stock In At The Market Offerings Net Of Issuance Costs1 Amount
IssuanceOfCommonStockInAtTheMarketOfferingsNetOfIssuanceCosts1Amount
41582000
CY2023Q4 rxst Other Comprehensive Loss
OtherComprehensiveLoss
-90000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-48608000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
160362000
CY2023 us-gaap Profit Loss
ProfitLoss
-48608000
CY2022 us-gaap Profit Loss
ProfitLoss
-66756000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4078000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3884000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
165000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
138000
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
287000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
552000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1769000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
6122000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1405000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
15746000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
11397000
CY2023 us-gaap Inventory Write Down
InventoryWriteDown
164000
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
752000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9325000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6094000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2749000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7555000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
562000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-789000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1250000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
635000
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2314000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4813000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41593000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-58850000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4814000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2393000
CY2023 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
255000000
CY2022 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
255000000
CY2023 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
272315000
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
212657000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22129000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
39950000
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
20000000
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2023 rxst Repayment Of Term Loan
RepaymentOfTermLoan
60000000
CY2022 rxst Repayment Of Term Loan
RepaymentOfTermLoan
-0
CY2023 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
54050000
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2023 rxst Proceeds From Issuance Of Common Stock In At The Market Offerings
ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings
42434000
CY2022 rxst Proceeds From Issuance Of Common Stock In At The Market Offerings
ProceedsFromIssuanceOfCommonStockInAtTheMarketOfferings
6050000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9473000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1778000
CY2023 rxst Payments For Employee Taxes Related To Stock Compensation
PaymentsForEmployeeTaxesRelatedToStockCompensation
-1423000
CY2022 rxst Payments For Employee Taxes Related To Stock Compensation
PaymentsForEmployeeTaxesRelatedToStockCompensation
-643000
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
153000
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
121000
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
622000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
587000
CY2023 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2235000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
145000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61524000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6332000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-9000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2192000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12577000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12595000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25172000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10403000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12595000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
2216000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
2187000
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
8000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3000
CY2023 rxst Interest Paid On Financing Leases
InterestPaidOnFinancingLeases
12000
CY2022 rxst Interest Paid On Financing Leases
InterestPaidOnFinancingLeases
18000
CY2023 rxst Interest Paid On Term Loan
InterestPaidOnTermLoan
3464000
CY2022 rxst Interest Paid On Term Loan
InterestPaidOnTermLoan
4239000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
46000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1090000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
102000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
311000
CY2023 rxst Operating Lease Obligations Incurred
OperatingLeaseObligationsIncurred
46000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2022 rxst Operating Lease Obligations Incurred
OperatingLeaseObligationsIncurred
1090000
CY2023 rxst Finance Lease Obligations Incurred
FinanceLeaseObligationsIncurred
102000
CY2022 rxst Finance Lease Obligations Incurred
FinanceLeaseObligationsIncurred
311000
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
282000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
299000
CY2023 rxst Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
145000
CY2022 rxst Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
133000
CY2023 rxst Reclassification Of Deferred Cost
ReclassificationOfDeferredCost
1390000
CY2022 rxst Reclassification Of Deferred Cost
ReclassificationOfDeferredCost
90000
CY2023 rxst Number Of Wholly Owned Subsidiaries
NumberOfWhollyOwnedSubsidiaries
1
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
127200000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
105800000
CY2023 rxst Operating Income Loss1
OperatingIncomeLoss1
50100000
CY2022 rxst Operating Income Loss1
OperatingIncomeLoss1
63300000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make informed estimates, judgments and assumptions that affect the reported amounts in the consolidated financial statements and disclosures in the accompanying notes as of the date of the accompanying consolidated financial statements. On an on-going basis, management evaluates the most critical estimates and assumptions for continued reasonableness. These estimates and assumptions involve judgments with respect to numerous factors that are difficult to predict. Actual results may differ materially from the estimates used in the preparation of the accompanying consolidated financial statements under different assumptions or conditions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s consolidated financial statements as of and for the year ended December 31, 2023 reflect the Company’s estimates of the impact of the macroeconomic environment, including the impact of inflation, higher interest rates and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of this filing.</span></p>
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
10000
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
75000
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
CY2023 rxst Increased Decreased In Restricted Cash
IncreasedDecreasedInRestrictedCash
50000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
711000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9692000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11834000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
711000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
761000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10403000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12595000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company’s policy is to invest cash in institutional money market funds and marketable securities of the U.S. government to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and short-term investments in money market funds and U.S. treasury bills. A portion of the Company's operating cash is held in accounts in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limits; however, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. The Company has not experienced material losses on cash equivalents and short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s products require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that the Company’s products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on the Company’s business and may impact business in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">future. In addition, after approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the device approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of the Company's products, product liability and the need to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 rxst Accounts Receivable Percentage
AccountsReceivablePercentage
0.10
CY2022 rxst Accounts Receivable Percentage
AccountsReceivablePercentage
0.10
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
89077000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49005000
CY2022Q4 rxst Deferred Revenue1
DeferredRevenue1
1187000
CY2021Q4 rxst Deferred Revenue1
DeferredRevenue1
540000
CY2023 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
3422000
CY2022 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
2052000
CY2023 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
2721000
CY2022 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
1405000
CY2023Q4 rxst Deferred Revenue1
DeferredRevenue1
1888000
CY2022Q4 rxst Deferred Revenue1
DeferredRevenue1
1187000
CY2023Q4 rxst Liability On Uncertain Tax Position
LiabilityOnUncertainTaxPosition
0
CY2022Q4 rxst Liability On Uncertain Tax Position
LiabilityOnUncertainTaxPosition
0
CY2023Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8092000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6408000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
5680000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
6494000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
4145000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2567000
CY2023Q4 us-gaap Inventory Gross
InventoryGross
17917000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
15469000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
496000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
634000
CY2023Q4 us-gaap Inventory Net
InventoryNet
17421000
CY2022Q4 us-gaap Inventory Net
InventoryNet
14835000
CY2023Q4 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
4400000
CY2022Q4 us-gaap Other Inventory Materials Supplies And Merchandise Under Consignment
OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
2800000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33539000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
30036000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22698000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19898000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10841000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10138000
CY2023 us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
4100000
CY2022 us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
3900000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
121965000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
102877000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
10637000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8537000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2045000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1348000
CY2023Q4 rxst Accrued Interest Current
AccruedInterestCurrent
0
CY2022Q4 rxst Accrued Interest Current
AccruedInterestCurrent
455000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2557000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2332000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15239000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12672000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-3542000
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-12793000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
9000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-9527000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-11366000
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-3266000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8300000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6100000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.649
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.631
CY2023 rxst Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.041
CY2022 rxst Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.027
CY2023 rxst Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life
SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife
P6Y
CY2022 rxst Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Life
SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedLife
P6Y1M6D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 rxst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend Yield
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividendYield
0
CY2023 rxst Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value
SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue
17.6
CY2022 rxst Shares Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Grant Date Fair Value
SharesBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageGrantDateFairValue
12.73
CY2022Q3 rxst Securities Issuable Value Under Self Registration Statement Form
SecuritiesIssuableValueUnderSelfRegistrationStatementForm
200000000
CY2022Q3 us-gaap Registration Payment Arrangement Term
RegistrationPaymentArrangementTerm
three years
CY2022Q3 us-gaap Registration Payment Arrangement Gains And Losses
RegistrationPaymentArrangementGainsAndLosses
200000000
CY2022 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
475875
CY2022Q4 rxst Common Stock Sale Underwriting Discounts And Commission Deducted
CommonStockSaleUnderwritingDiscountsAndCommissionDeducted
6000000
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8364218
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11816582
CY2022Q4 rxst Closing Stock Price
ClosingStockPrice
12.67
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-48590000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-66750000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
2000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
3000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48588000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66747000
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
21000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
8000
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-1000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
1000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
20000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-14908000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12793000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14908000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
73600000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
70179000
CY2023Q4 rxst Deferred Tax Asset Amortization
DeferredTaxAssetAmortization
81000
CY2022Q4 rxst Deferred Tax Asset Amortization
DeferredTaxAssetAmortization
99000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
10923000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4879000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3292000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2960000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11271000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
9202000
CY2023Q4 rxst Deferred Tax Asset Right Of Use Of Liability
DeferredTaxAssetRightOfUseOfLiability
752000
CY2022Q4 rxst Deferred Tax Asset Right Of Use Of Liability
DeferredTaxAssetRightOfUseOfLiability
1204000
CY2023Q4 rxst Deferred Tax Asset Depreciation
DeferredTaxAssetDepreciation
1035000
CY2022Q4 rxst Deferred Tax Asset Depreciation
DeferredTaxAssetDepreciation
779000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2934000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2332000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
103888000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
91634000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
103242000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
90471000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
646000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1163000
CY2023Q4 rxst Deferred Tax Asset Right Of Use Of Asset
DeferredTaxAssetRightOfUseOfAsset
646000
CY2022Q4 rxst Deferred Tax Asset Right Of Use Of Asset
DeferredTaxAssetRightOfUseOfAsset
1163000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
646000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1163000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
10203000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
14017000
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.041
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1992000
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.035
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
2358000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.037
CY2023 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-1805000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.019
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-1269000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.003
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
150000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.024
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1625000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.005
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
246000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.002
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
105000
CY2023 rxst Effective Income Tax Rate Reconciliation Limitation And Credit Carry Forwards Subject To Expiration
EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration
-0.022
CY2023 rxst Income Tax Reconciliation Limitation And Credit Carry Forwards Subject To Expiration
IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration
1070000
CY2022 rxst Effective Income Tax Rate Reconciliation Limitation And Credit Carry Forwards Subject To Expiration
EffectiveIncomeTaxRateReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration
-0.015
CY2022 rxst Income Tax Reconciliation Limitation And Credit Carry Forwards Subject To Expiration
IncomeTaxReconciliationLimitationAndCreditCarryForwardsSubjectToExpiration
988000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.005
CY2023 rxst Income Tax Reconciliation Tax Credit Other
IncomeTaxReconciliationTaxCreditOther
-239000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0
CY2022 rxst Income Tax Reconciliation Tax Credit Other
IncomeTaxReconciliationTaxCreditOther
27000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.263
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
12793000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.223
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
14908000
CY2023 rxst Effective Income Tax Reconciliation Tax Credits
EffectiveIncomeTaxReconciliationTaxCredits
0
CY2023 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
20000
CY2022 rxst Effective Income Tax Reconciliation Tax Credits
EffectiveIncomeTaxReconciliationTaxCredits
0
CY2022 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
9000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
12800000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
14900000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
311200000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
148600000
CY2023Q4 rxst Taxable Income Offset Percentage
TaxableIncomeOffsetPercentage
0.80
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
311200000
CY2023Q4 rxst Federal Operating Loss Carry Forwards Not Expire
FederalOperatingLossCarryForwardsNotExpire
204800000
CY2023Q4 rxst Taxable Income Offset Percentage
TaxableIncomeOffsetPercentage
0.80
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
148600000
CY2023Q4 rxst State Operating Loss Carry Forwards Not Expire
StateOperatingLossCarryForwardsNotExpire
25300000
CY2023Q4 rxst Taxable Income Offset Percentage
TaxableIncomeOffsetPercentage
0.80
CY2023Q4 rxst Federal Operating Loss Carry Forwards
FederalOperatingLossCarryForwards
9900000
CY2023Q4 rxst State Operating Loss Carry Forwards
StateOperatingLossCarryForwards
9300000
CY2023 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
Pursuant to Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of the Company’s net operating loss and R&D credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a three-year period.
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3494000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3013000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
683000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
481000
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
67000
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4244000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3494000
CY2023 us-gaap Foreign Earnings Repatriated
ForeignEarningsRepatriated
0
CY2022 us-gaap Foreign Earnings Repatriated
ForeignEarningsRepatriated
0
CY2022Q2 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P34M
CY2022Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-03-31
CY2022Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
11410
CY2023Q1 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
5319
CY2023Q1 us-gaap Operations Commenced Date1
OperationsCommencedDate1
2023-03-01
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2444000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3943000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
156000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
206000
CY2023Q4 rxst Total Lease Assets
TotalLeaseAssets
2600000
CY2022Q4 rxst Total Lease Assets
TotalLeaseAssets
4149000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1764000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1818000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
37000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
152000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1093000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2813000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
118000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
43000
CY2023Q4 rxst Total Lease Liabilities
TotalLeaseLiabilities
3012000
CY2022Q4 rxst Total Lease Liabilities
TotalLeaseLiabilities
4826000
CY2023 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
12000
CY2022 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
18000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1970000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
56000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1054000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
40000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
90000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
40000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
11000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
40000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
10000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
34000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3135000
CY2023Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
210000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
278000
CY2023Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
55000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2857000
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
155000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M8D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y5M1D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M13D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M14D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.104
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.103
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.14
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.095
CY2023 us-gaap Legal Fees
LegalFees
0
CY2022 us-gaap Legal Fees
LegalFees
0
CY2021Q3 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.02
CY2023 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.25
CY2023 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
900000
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
688000

Files In Submission

Name View Source Status
0000950170-24-022073-index-headers.html Edgar Link pending
0000950170-24-022073-index.html Edgar Link pending
0000950170-24-022073.txt Edgar Link pending
0000950170-24-022073-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img50815396_0.jpg Edgar Link pending
img50815396_1.jpg Edgar Link pending
img50815396_2.jpg Edgar Link pending
img50815396_3.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxst-20231231.htm Edgar Link pending
rxst-20231231.xsd Edgar Link pending
rxst-ex10_27.htm Edgar Link pending
rxst-ex23_1.htm Edgar Link pending
rxst-ex31_1.htm Edgar Link pending
rxst-ex31_2.htm Edgar Link pending
rxst-ex32_1.htm Edgar Link pending
rxst-ex32_2.htm Edgar Link pending
rxst-ex97_1.htm Edgar Link pending
Show.js Edgar Link pending
rxst-20231231_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable